clindamycin q6hrs

ApprovedSmall molecule

UUniversity of Louisville

clindamycin q6hrs is one of 51 small molecule programs targeting Osteomyelitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteomyelitisActive, not recruiting

OsteomyelitisApproved

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Osteomyelitis

#DrugCompanyPhaseTrials

Azulfidine

Pfizer

Approved

1 2

Rifadin

Sanofi

Approved

1 3

Cipro

Priftin

Maxipime

Acanya

Avelox

Mycobutin

Ceftin

PPhiladelphia Eye Associates

Approved

—10

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteomyelitis1 trial

Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis

Not yet recruiting·UUniversity of Louisville·Phase 4·NCT05867654·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for clindamycin q6hrs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — clindamycin q6hrs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for clindamycin q6hrs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Louisville company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Louisville

clindamycin q6hrs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteomyelitis1 trial

References

Drug Info

Quick Facts

Related News